SCHEMBL1157577

SCHEMBL1157577

COc1ccc(NCc2ccccc2C)cc1OC1CCCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.65
MAPT P10636 5/20 0.51
GAA P10253 5/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
GLA P06280 1/20 0.51
CASP1 P29466 1/20 0.51
HSD17B10 Q99714 1/20 0.51
POLB P06746 1/20 0.51
PDE4A P27815 6/20 0.49
PDE4B Q07343 4/20 0.49
PDE4C Q08493 4/20 0.49
PDE4D Q08499 4/20 0.49
MAPK1 P28482 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
HPGD P15428 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
PDE5A O76074 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157601 0.90 MEN1 (0.58) EPHX2MAPTGAAMEN1KMT2A
SCHEMBL1157311 0.87 POLB (0.53) EPHX2MAPTGAAMEN1KMT2A
SCHEMBL1157360 0.85 EPHX2 (0.67) EPHX2MAPTGAAMEN1KMT2A
SCHEMBL3404412 0.85 MAPT (0.68) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL1157332 0.84 PDE4A (0.58) MEN1KMT2APOLBPDE4APDE4B
SCHEMBL1157308 0.84 MAPT (0.56) EPHX2MAPTGAAMEN1KMT2A
SCHEMBL1157697 0.82 POLB (0.52) EPHX2MAPTGAAMEN1KMT2A
SCHEMBL1157627 0.81 POLB (0.47) EPHX2MAPTGAAKDM4EALDH1A1
SCHEMBL1157307 0.80 POLB (0.46) EPHX2MEN1KMT2APOLBPDE4A
SCHEMBL1157585 0.80 PDE5A (0.54) EPHX2MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 US disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 US disclosed
EP-1539697-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS Memory Pharmaceutical Corporation (US) 2005-06-15 EP disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 US disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 US disclosed
WO-2004009552-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 EP disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 US disclosed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A EPHX2 1470/4885MAPT 4439/4885GAA 647/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A EPHX2 1470/4885MAPT 4439/4885GAA 647/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A EPHX2 1470/4885MAPT 4439/4885GAA 647/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B EPHX2 1614/4885MAPT 4102/4885GAA 786/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B EPHX2 1614/4885MAPT 4102/4885GAA 786/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A EPHX2 1684/4885MAPT 3913/4885GAA 770/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A EPHX2 1684/4885MAPT 3913/4885GAA 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.